Add Formweb to your mobile device
Search results for:
pegfilgrastim
pegfilgrastim
Brand names: Fulphila, Fulphila (pegfilgrastim-jmdb), Fylnetra, Neulasta, Neulasta Onpro Kit, Nyvepria, Nyvepria (pegfilgrastim-apgf), Stimufend, Udenyca (pegfilgrastim-cbqv), Udenyca Autoinjector, Udenyca Onbody, Udenyca Prefilled Syringe, Ziextenzo, Ziextenzo (pegfilgrastim-bmez)
| Form | Strength | ANAN | ASMP | LACH | LALK | LOHH | LOLR | LOWC | SDSD | SESE | SFSF | Formulary Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLUTION, SUBCUTANEOUS | 6 mg/0.6 mL; apgf 6 mg/0.6 mL; bmez 6 mg/0.6 mL; cbqv 6 mg/0.6 mL; fpgk 6 mg/0.6 mL; jmdb 6 mg/0.6 mL; pbbk 6 mg/0.6 mL | SEE COMMENTS SEE BIOSIMILAR AND REFERENCE PRODUCTS INTERCHANGE LIST TO THE RIGHT |
Last updated: Oct. 15, 2025
- Therapeutic Interchange: Biosimilar and Reference Products Conversion List for Adults
- Do Not Tube-LALK
- Restricted: Restricted to outpatient use only and inpatient use restricted to specific criteria. Pegfilgrastim on-body injector products are restricted to outpatient use only.
Medications Approved for Automatic Therapeutic Interchange Dosage Conversion Guidelines
(Note: “Therapeutic Interchange” should be placed in the order comments)
Biosimilar and Reference Products Interchange List for Adults
Medication
Reference Drug or Biosimilar
Formulary Status
Automatic Therapeutic Interchange
Inpatient1
Outpatient
Fylnetra (pegfilgrastim-pbbk)
Biosimilar
Formulary, inpatient use restricted to criteria2
(preferred)
Use Fylnetra when criteria2 met or recommend Granix
Use Fylnetra unless third party payer requires other pegfilgrastim product
Udenyca (pegfilgrastim-cbqv) Ziextenzo (pegfilgrastim-bmez) Nyvepria (pegfilgrastim-apgf) Stimufend (pegfilgrastim-fpgk) Fulphila (pegfilgrastim-imdb)
Biosimilars
Formulary, restricted to OP
(not preferred)
Interchange to Fylnetra when criteria2 met or recommend Granix
Interchange to Fylnetra unless third party payer requires other pegfilgrastim product
Neulasta (pegfilgrastim)
Reference
Neulasta, Udenyca, and Stimufend are the only pegfilgrastim products with approval for hematopoietic radiation injury syndrome. Pegfilgrastim On-body will remain restricted to outpatient use only.
2Inpatient Pegfilgrastim Criteria:
Inpatient pegfilgrastim reminders: Patients meeting criteria will receive the formulary inpatient pegfilgrastim product. The NFT process must be completed for other inpatient pegfilgrastim products. Filgrastim is the preferred WBC growth factor for inpatient use; only a small number of patients will meet criteria for inpatient pegfilgrastim use.